| aOR = Exp(B) | SE | Wald χ2 | 95% confidence interval | p value |
---|
Age (years) | 0.97 | 0.03 | 0.84 | 0.92–1.0 | 0.360 |
Sex | 3.6 | 0.68 | 3.6 | 0.96–13.6 | 0.058 |
MIDASRes | 2.1 | 0.56 | 1.8 | 0.70–6.3 | 0.185 |
MMDRes | 7.1 | 0.58 | 11.3 | 2.3–22.4 | 0.001 |
- Legend: aOR: adjusted Odds Ratio; MIDASRes: Patients with a MIDAS reduction of at least 50% at T3. MMDRes: Patients with MMDs reduction of at least 50% at T3. +T3: follow-up visit at three months after first erenumab administration. Variables tested but not included in the final model according to a stepwise analysis: baseline general health score, baseline HADS-D score, days of acute drug intake at baseline, and use of preventive treatment at baseline